rs11124945 - PLEKHH2
Magnitude 4.5 · 1 study on file
Reported associations
-
Genome-Wide Association Study Identifies Pharmacogenomic Loci Linked with Specific Antihypertensive Drug Treatment and New-Onset Diabetes - Unknown journal (n.d.) · Unknown authors · PubMed 27670767
ABSTRACT: We conducted a discovery genome-wide association study with expression quantitative trait loci (eQTL) annotation of new-onset diabetes (NOD) among European Americans, who were exposed to a calcium channel blocker-based strategy (CCB strategy) or a β-blocker-based strategy (β-blocker strategy) in the INternational VErapamil SR Trandolapril STudy. Replication of the top signal from the SNP*treatment interaction analysis was attempted in Hispanic and African Americans, and a joint meta-analysis was performed (total 334 NOD cases and 806 matched controls). PLEKHH2 rs11124945 at 2p21 interacted with antihypertensive exposure for NOD (meta-analysis p=5.3×10−8). rs11124945 G allele carriers had lower odds for NOD when exposed to the β-blocker strategy compared with the CCB strateg
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
beta-blocker preference for antihypertensive therapy Moderate
PLEKHH2 rs11124945 G allele carriers show lower new-onset diabetes risk with beta-blockers versus calcium channel blockers
If starting antihypertensive therapy, discuss beta-blocker option with doctor
-
calcium channel blocker preference in blood pressure therapy Moderate
PLEKHH2 rs11124945 A/A homozygotes show lower new-onset diabetes risk with calcium channel blockers versus beta-blockers
If starting antihypertensive therapy, discuss CCB option with doctor